Lv2
178 积分 2022-03-25 加入
Baseline PSMA‐PET/CT as a predictor of PSA persistence following radical prostatectomy in high‐risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy
28天前
已完结
Immunotherapy of High Risk Non-Muscle Invasive Bladder Cancer
29天前
已完结
PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC)
2个月前
已完结
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection
2个月前
已完结
Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer
2个月前
已完结
A Phase II Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder
2个月前
已完结
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma
2个月前
已完结
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
2个月前
已完结
Initial [18F]DCFPyL PET/CT in treatment-naïve prostate cancer: correlation with post-ADT PSA outcomes and recurrence
3个月前
已完结
Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study
5个月前
已完结
皖公网安备34019202002308
